Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition

OBJECTIVE: Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ketoacidosis (euDKA) in hopes that it will enhance recognition of this potentially life-threatening complicatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Anne L., Buschur, Elizabeth O., Buse, John B., Cohan, Pejman, Diner, Jamie C., Hirsch, Irl B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2015
Materias:
Clinical Care/Education/Nutrition/Psychosocial Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542270/
https://www.ncbi.nlm.nih.gov/pubmed/26078479
http://dx.doi.org/10.2337/dc15-0843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542270/
https://www.ncbi.nlm.nih.gov/pubmed/26078479
http://dx.doi.org/10.2337/dc15-0843

Ejemplares similares